Socioeconomic disability in psoriasis.
Seidler, E M, and A B Kimball. 2009. “Socioeconomic Disability in Psoriasis.”. The British Journal of Dermatology 161 (6): 1410-2.
Search
Search results
3115 results found
Pregnancy outcomes in psoriasis: why do we know so little?
Horn, Elizabeth J, Christina D Chambers, Alan Menter, Alexa B Kimball, and International Psoriasis Council. 2009. “Pregnancy Outcomes in Psoriasis: Why Do We Know so Little?”. Journal of the American Academy of Dermatology 61 (2): e5-8.
Biologicals in the treatment of psoriasis.
Boker, Andreas, Alexa B Kimball, and Gabriela Rolz-Cruz. 2007. “Biologicals in the Treatment of Psoriasis.”. Current Opinion in Investigational Drugs (London, England : 2000) 8 (11): 939-46.
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis.
Chan, Jason R, Wendy Blumenschein, Erin Murphy, Caroline Diveu, Maria Wiekowski, Susan Abbondanzo, Linda Lucian, et al. 2006. “IL-23 Stimulates Epidermal Hyperplasia via TNF and IL-20R2-Dependent Mechanisms With Implications for Psoriasis Pathogenesis.”. The Journal of Experimental Medicine 203 (12): 2577-87.
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis.
Kimball, Alexa B, Philippe Szapary, Ulrich Mrowietz, Kristian Reich, Richard G Langley, Yin You, Ming-Chun Hsu, Newman Yeilding, Daniel J Rader, and Nehal N Mehta. 2012. “Underdiagnosis and Undertreatment of Cardiovascular Risk Factors in Patients With Moderate to Severe Psoriasis.”. Journal of the American Academy of Dermatology 67 (1): 76-85.
Teaching empathy to undergraduate medical students using a temporary tattoo simulating psoriasis.
Latham, Lesley, Aimee MacDonald, Alexa B Kimball, and Richard G Langley. 2012. “Teaching Empathy to Undergraduate Medical Students Using a Temporary Tattoo Simulating Psoriasis.”. Journal of the American Academy of Dermatology 67 (1): 93-9.
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
Gordon, Kenneth B, Kim A Papp, Richard G Langley, Vincent Ho, Alexa B Kimball, Cynthia Guzzo, Newman Yeilding, et al. 2012. “Long-Term Safety Experience of Ustekinumab in Patients With Moderate to Severe Psoriasis (Part II of II): Results from Analyses of Infections and Malignancy from Pooled Phase II and III Clinical Trials.”. Journal of the American Academy of Dermatology 66 (5): 742-51.
The impact of psoriasis on pregnancy outcomes.
Lima, Xinaida T, Vanitha Janakiraman, Michael D Hughes, and Alexandra B Kimball. 2012. “The Impact of Psoriasis on Pregnancy Outcomes.”. The Journal of Investigative Dermatology 132 (1): 85-91.
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Kimball, Alexa B, Arielle G Bensimon, Annie Guérin, Andrew P Yu, Eric Q Wu, Martin M Okun, Yanjun Bao, Shiraz R Gupta, and Parvez M Mulani. 2011. “Efficacy and Safety of Adalimumab Among Patients With Moderate to Severe Psoriasis With Co-Morbidities: Subanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.”. American Journal of Clinical Dermatology 12 (1): 51-62.
Economic burden of comorbidities in patients with psoriasis is substantial.
Kimball, A B, A Guérin, M Tsaneva, A P Yu, E Q Wu, S R Gupta, Y Bao, and P M Mulani. 2011. “Economic Burden of Comorbidities in Patients With Psoriasis Is Substantial.”. Journal of the European Academy of Dermatology and Venereology : JEADV 25 (2): 157-63.